Elastase inhibitor - Bayer
Latest Information Update: 07 Mar 2013
At a glance
- Originator Bayer HealthCare
- Class
- Mechanism of Action Pancreatic elastase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Chronic obstructive pulmonary disease
Most Recent Events
- 07 Mar 2013 Discontinued - Phase-I for Chronic obstructive pulmonary disease in USA (unspecified route)
- 29 Apr 2008 Phase I development is ongoing
- 09 Oct 2006 Phase-I clinical trials in Chronic obstructive pulmonary disease (unspecified route)